AU2001259215A1 - Human anti-cd40 antibodies and methods of making and using same - Google Patents
Human anti-cd40 antibodies and methods of making and using sameInfo
- Publication number
- AU2001259215A1 AU2001259215A1 AU2001259215A AU5921501A AU2001259215A1 AU 2001259215 A1 AU2001259215 A1 AU 2001259215A1 AU 2001259215 A AU2001259215 A AU 2001259215A AU 5921501 A AU5921501 A AU 5921501A AU 2001259215 A1 AU2001259215 A1 AU 2001259215A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- making
- methods
- same
- human anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20060100P | 2000-04-28 | 2000-04-28 | |
US60200601 | 2000-04-28 | ||
PCT/US2001/013672 WO2001083755A2 (en) | 2000-04-28 | 2001-04-27 | Human anti-cd40 antibodies and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001259215A1 true AU2001259215A1 (en) | 2001-11-12 |
Family
ID=22742393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001259215A Abandoned AU2001259215A1 (en) | 2000-04-28 | 2001-04-27 | Human anti-cd40 antibodies and methods of making and using same |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001259215A1 (en) |
TW (1) | TWI264467B (en) |
WO (1) | WO2001083755A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
WO2002028481A2 (en) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
EP1349575A2 (en) * | 2000-11-03 | 2003-10-08 | University Of South Florida | Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
WO2003028809A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Methods of therapy for b-cell malignancies |
WO2003029296A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
AU2002346581A1 (en) * | 2001-11-26 | 2003-06-10 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
DK1682178T3 (en) * | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Methods for therapy of cancers expressing the CD-40 antigen |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
JP4765037B2 (en) * | 2003-11-04 | 2011-09-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Use of antagonist anti-CD40 monoclonal antibodies for the treatment of chronic lymphocytic leukemia |
DE602004028272D1 (en) * | 2003-11-04 | 2010-09-02 | Novartis Vaccines & Diagnostic | USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA |
DK1684869T3 (en) * | 2003-11-04 | 2011-10-31 | Novartis Vaccines & Diagnostic | Method of Therapy for B-Cell-Related Cancer Diseases |
CA2564296A1 (en) * | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
WO2007053767A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
MEP39508A (en) | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
KR101620642B1 (en) | 2007-11-07 | 2016-05-12 | 제넨테크, 인크. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
US8518410B2 (en) | 2009-03-10 | 2013-08-27 | Baylor Research Institute | Fusion protein with HIV antigen |
WO2010065819A1 (en) * | 2008-12-05 | 2010-06-10 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
DK2406286T3 (en) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
BRPI1009454A2 (en) | 2009-03-10 | 2019-09-24 | Baylor Res Institute | cancer vaccines targeted at antigen presenting cells |
JP5836929B2 (en) | 2009-04-18 | 2015-12-24 | ジェネンテック, インコーポレイテッド | Method for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibody |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
TW201300418A (en) | 2011-03-25 | 2013-01-01 | Baylor Res Inst | Compositions and methods to immunize against hepatitis C virus |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
EP3094652B1 (en) | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
EP3180087B1 (en) | 2014-08-12 | 2019-03-13 | Alligator Bioscience AB | Combination therapies with anti cd40 antibodies |
MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
AU2016331819B2 (en) | 2015-09-30 | 2023-08-24 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding human CD40 and methods of use |
MA45488A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, KITS AND APPARATUS |
MX2018005550A (en) | 2015-11-03 | 2019-07-18 | Janssen Biotech Inc | Antibodies specifically binding tim-3 and their uses. |
IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
US20180044430A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them |
MA45919A (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech Inc | DESIGN OF MODIFIED ANTIBODIES AND OTHER MOLECULES CONTAINING FC DOMAIN WITH ENHANCED AGONISM AND EFFECTOR FUNCTIONS |
US11866465B2 (en) | 2017-04-27 | 2024-01-09 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
RU2770209C2 (en) | 2017-05-24 | 2022-04-14 | ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ | Cd40 ligand therapeutic antibodies |
KR102198998B1 (en) * | 2017-06-01 | 2021-01-07 | 서울대학교 산학협력단 | Novel anti-cd40 antibodies and uses thereof |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
WO2020047299A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
JP7407822B2 (en) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Single chain chimeric polypeptides and their uses |
JP7449292B2 (en) | 2018-08-30 | 2024-03-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Treatments for age-related disorders |
CN109678959B (en) * | 2019-02-22 | 2020-12-08 | 北京免疫方舟医药科技有限公司 | anti-CD 40 antibodies and uses thereof |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1834671A3 (en) * | 1992-07-09 | 2013-05-22 | Novartis Vaccines and Diagnostics, Inc. | A method for generation of antibodies to cell surface molecules |
CA2172376C (en) * | 1993-10-01 | 2008-11-18 | William C. Fanslow, Iii | Antibodies to cd40 |
ATE390933T1 (en) * | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
EP0823941A4 (en) * | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
WO2000000156A2 (en) * | 1998-06-26 | 2000-01-06 | Trustees Of Dartmouth College | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands |
-
2001
- 2001-04-27 WO PCT/US2001/013672 patent/WO2001083755A2/en active Application Filing
- 2001-04-27 AU AU2001259215A patent/AU2001259215A1/en not_active Abandoned
- 2001-04-30 TW TW090110333A patent/TWI264467B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001083755A2 (en) | 2001-11-08 |
TWI264467B (en) | 2006-10-21 |
WO2001083755A3 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001259215A1 (en) | Human anti-cd40 antibodies and methods of making and using same | |
AU2001261160A1 (en) | Prosthesis and method of making | |
ZA200305825B (en) | Modified antibodies and methods of use | |
AU2002320058A1 (en) | Magnetic-nanoparticle conjugates and methods of use | |
AU2002320456A1 (en) | Removable stent and method of using the same | |
IL206980A0 (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
AU2001270943A1 (en) | Surgical instrument and method of using the same | |
WO2002030986A3 (en) | HUMANIZED ANTI-LT-β-R ANTIBODIES | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU2001251358A1 (en) | Prion-binding ligands and methods of using same | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
AU2001256325A1 (en) | Human and humanized fap-alpha-specific antibodies | |
AU2001272840A1 (en) | Adjustable chair and method of use | |
AU2002340167A1 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
AU2002324965A1 (en) | Artificial kidney and methods of using same | |
AU2002326751A1 (en) | Immunoglobulin e vaccines and methods of use thereof | |
AU7676300A (en) | Human anti-adipocyte monoclonal antibodies and their use | |
AU2002211183A1 (en) | Prosthetic construct and methods for its manufacture and use | |
AU2001260774A1 (en) | Bio-support and preparing method of the same | |
AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
HK1046646A1 (en) | Preparations and method of producing the same | |
AU2002363938A1 (en) | Methods and use of motoneuronotropic factors | |
AU2001261375A1 (en) | Human caspase-12 materials and methods | |
AU2002310237A1 (en) | Sponge-derived terpenoids and methods of use | |
AU2003276844A1 (en) | Formulations of modified antibodies and methods of making the same |